Cite
EP08.02-146 Proposal of Foretinib as Second-Line TKI after Capmatinib/Tepotinib Treatment Failure in NSCLC with MET Exon 14 Mutation.
MLA
Fujino, T., et al. “EP08.02-146 Proposal of Foretinib as Second-Line TKI after Capmatinib/Tepotinib Treatment Failure in NSCLC with MET Exon 14 Mutation.” Journal of Thoracic Oncology, vol. 17, no. 9, Sept. 2022, pp. S472–73. EBSCOhost, https://doi.org/10.1016/j.jtho.2022.07.829.
APA
Fujino, T., Suda, K., Koga, T., Hamada, A., Ohara, S., Chiba, M., Shimoji, M., Takemoto, T., Soh, J., & Mitsudomi, T. (2022). EP08.02-146 Proposal of Foretinib as Second-Line TKI after Capmatinib/Tepotinib Treatment Failure in NSCLC with MET Exon 14 Mutation. Journal of Thoracic Oncology, 17(9), S472–S473. https://doi.org/10.1016/j.jtho.2022.07.829
Chicago
Fujino, T., K. Suda, T. Koga, A. Hamada, S. Ohara, M. Chiba, M. Shimoji, T. Takemoto, J. Soh, and T. Mitsudomi. 2022. “EP08.02-146 Proposal of Foretinib as Second-Line TKI after Capmatinib/Tepotinib Treatment Failure in NSCLC with MET Exon 14 Mutation.” Journal of Thoracic Oncology 17 (9): S472–73. doi:10.1016/j.jtho.2022.07.829.